Gonzalez-Ponce Fabiola, Gamez-Nava Jorge Ivan, Jacobo-Cuevas Heriberto, Ponce-Guarneros Juan Manuel, Valdivia-Tangarife Edgar Ricardo, Nava-Valdivia Cesar Arturo, Rodriguez-Jimenez Norma Alejandra, Ramirez-Villafaña Melissa, Gomez-Ramirez Eli Efrain, Gonzalez-Vazquez Sergio Antonio, Brambila-Tapia Aniel Jessica Leticia, Olivas-Flores Eva Maria, Totsuka-Sutto Sylvia, Cardona-Muñoz Ernesto German, Gonzalez-Lopez Laura
Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Programa de Maestría en Salud Publica, Departamento de Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Int J Mol Sci. 2025 Aug 25;26(17):8232. doi: 10.3390/ijms26178232.
Rheumatoid arthritis (RA) is a highly prevalent chronic inflammatory rheumatic disorder leading to functional impairment and sequels. The search for new biomarkers helping in detecting RA subjects of high risk of functional disability is required. Studies showing high follistatin levels in RA have been described; however, none of them have placed focus on the role of follistatin as marker of deteriorated functionality. We aim to identify whether follistatin concentrations could be a potential biomarker of physical disability and disease activity in RA patients. Fifty-seven female RA subjects and 20 age-gender-matched controls were included in a cross-sectional evaluation. An assessment of clinical characteristics, grip strength, gait speed, and muscle mass was conducted. In RA subjects, disability was assessed using HAQ-DI and active disease using the DAS28-ESR. Follistatin levels were measured by ELISA. We compared (a) RA + functional disability and (b) RA + preserved physical function. Serum follistatin levels were increased in RA subjects compared to controls (175 ± 119 vs. 133 ± 47; = 0.030). Follistatin levels correlated with deteriorated physical function levels (r = 0.491; < 0.001) and severe activity (r = 0.344; = 0.009). The RA + functional disability group, as compared to the RA + preserved physical function group, had higher serum follistatin levels (218 ± 159 vs. 141 ± 59; = 0.030), lower grip strength (7.9 ± 4.6 vs. 14.5 ± 5.1; < 0.001), reduced gait speed (0.77 ± 0.20 vs. 0.92 ± 0.20; = 0.010), as well as higher proportions of tender joints ≥4 (48% vs. 16%; = 0.008), and higher disease activity scores (3.8 ± 1.5 vs. 2.8 ± 1.2; = 0.008). We concluded that higher follistatin levels are associated with physical functional impairment and the severity of disease activity in women with RA. Future studies are required to evaluate whether these follistatin levels can be related to other outcomes such as labor disability, hospitalization, and falls.
类风湿关节炎(RA)是一种高度流行的慢性炎症性风湿性疾病,可导致功能障碍和后遗症。需要寻找有助于检测有功能残疾高风险的RA患者的新生物标志物。已有研究报道RA患者中卵泡抑素水平较高;然而,这些研究均未关注卵泡抑素作为功能恶化标志物的作用。我们旨在确定卵泡抑素浓度是否可能是RA患者身体残疾和疾病活动的潜在生物标志物。57名女性RA患者和20名年龄、性别匹配的对照者纳入横断面评估。对临床特征、握力、步速和肌肉质量进行评估。在RA患者中,使用健康评估问卷残疾指数(HAQ-DI)评估残疾情况,使用28个关节疾病活动评分(DAS28-ESR)评估疾病活动度。通过酶联免疫吸附测定法(ELISA)测量卵泡抑素水平。我们比较了(a)RA + 功能残疾组和(b)RA + 身体功能保留组。与对照组相比,RA患者血清卵泡抑素水平升高(175±119 vs. 133±47;P = 0.030)。卵泡抑素水平与身体功能恶化程度相关(r = 0.491;P < 0.001),与疾病严重活动度相关(r = 0.344;P = 0.009)。与RA + 身体功能保留组相比,RA + 功能残疾组血清卵泡抑素水平更高(218±159 vs. 141±59;P = 0.030),握力更低(7.9±4.6 vs. 14.5±5.1;P < 0.001),步速减慢(0.77±0.20 vs. 0.92±0.20;P = 0.010),压痛关节≥4个的比例更高(48% vs. 16%;P = 0.008),疾病活动评分更高(3.8±1.5 vs. 2.8±1.2;P = 0.008)。我们得出结论,较高的卵泡抑素水平与RA女性患者的身体功能损害和疾病活动严重程度相关。未来需要进行研究,以评估这些卵泡抑素水平是否与其他结局相关,如劳动能力丧失、住院和跌倒。